Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Total Liabilities (2016 - 2025)

Integra Lifesciences Holdings' Total Liabilities history spans 17 years, with the latest figure at $2.6 billion for Q4 2025.

  • For Q4 2025, Total Liabilities rose 2.66% year-over-year to $2.6 billion; the TTM value through Dec 2025 reached $2.6 billion, up 2.66%, while the annual FY2025 figure was $2.6 billion, 2.66% up from the prior year.
  • Total Liabilities for Q4 2025 was $2.6 billion at Integra Lifesciences Holdings, down from $2.6 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $2.6 billion in Q2 2025 and bottomed at -$1.7 billion in Q2 2022.
  • The 5-year median for Total Liabilities is $2.1 billion (2021), against an average of $1.7 billion.
  • The largest annual shift saw Total Liabilities tumbled 179.38% in 2021 before it skyrocketed 234.49% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $2.1 billion in 2021, then decreased by 0.58% to $2.1 billion in 2022, then rose by 5.21% to $2.2 billion in 2023, then rose by 13.58% to $2.5 billion in 2024, then rose by 2.66% to $2.6 billion in 2025.
  • Per Business Quant, the three most recent readings for IART's Total Liabilities are $2.6 billion (Q4 2025), $2.6 billion (Q3 2025), and $2.6 billion (Q2 2025).